Troutman Pepper advised Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, in raising $62.5 million of committed capital in a Series C financing. New investor Sectoral Asset Management led the round. Also participating were new investors Alpha Wave Ventures, NexPoint, and others, joining existing investors Morningside Ventures, Seligman Investments, and Tao Capital Partners.
Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep.
The Troutman Pepper team advising Apnimed includes Chris Miller, Daniel Sieck, Stephen Fox, Jake McDonough, Joseph Goldman, Michael Crumbock, Tracey Diamond, Judith O’Grady, Sean McConnell, Noreen Onimus, Callan Stein, and Angelo Stio, among others.
Apnimed has been a member of Troutman Pepper’s Startup and Early-Stage Entrepreneurial Development (SEED) Program since the company’s inception. The program combines the resources of an experienced, multidisciplinary team into an affordable package for startups, early-stage, and fast-growing companies. Clients receive legal counsel, mentoring, relationship building opportunities, and more.